MBL Inks Pact with Envoy, Provides Access to RIP-Chip

Mar 15, 2011

NEW YORK (GenomeWeb News) – Medical & Biological Laboratories today announced it has signed a non-exclusive agreement with Envoy Therapeutics to provide it access to MBL's RIP-Chip technology.

Under the terms of the deal, MBL will receive an upfront payment of an undisclosed amount, annual licensing fees and potential milestone payments. Envoy will use the RIP-Chip for drug discovery and development.

Further terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Featured White Papers

iPSC & CRISPR/Cas9 Technologies Enable Precise & Controlled Physiologically Relevant Disease Modeling for Basic & Applied Research

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu